Insider Buying: FocalTherics (NASDAQ:FOCL) General Counsel Purchases $23,750.00 in Stock

FocalTherics (NASDAQ:FOCL) General Counsel Sanket Shah acquired 5,000 shares of the stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average price of $4.75 per share, for a total transaction of $23,750.00. Following the transaction, the general counsel directly owned 72,500 shares of the company’s stock, valued at $344,375. This represents a 7.41% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

FocalTherics Stock Performance

NASDAQ:FOCL opened at $4.76 on Monday. FocalTherics has a 52-week low of $1.30 and a 52-week high of $6.40. The company’s fifty day simple moving average is $5.39. The company has a quick ratio of 0.99, a current ratio of 1.34 and a debt-to-equity ratio of 1.79. The company has a market capitalization of $178.40 million, a price-to-earnings ratio of -4.62 and a beta of -0.04.

FocalTherics (NASDAQ:FOCL) last announced its earnings results on Friday, August 14th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The business had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 175.45% and a negative net margin of 56.26%. Equities analysts forecast that FocalTherics will post -0.78 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently weighed in on FOCL. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of FocalTherics in a research report on Tuesday, June 2nd. Wall Street Zen lowered shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday. Piper Sandler reissued a “neutral” rating and issued a $4.00 price target on shares of FocalTherics in a research note on Friday. Finally, Mizuho set a $15.00 price target on shares of FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $7.75.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in FOCL. SmartHarvest Portfolios LLC bought a new position in shares of FocalTherics in the 1st quarter worth approximately $38,000. Lido Advisors LLC bought a new stake in shares of FocalTherics during the first quarter valued at approximately $40,000. Kovack Advisors Inc. purchased a new stake in FocalTherics in the fourth quarter worth $53,000. Leonteq Securities AG purchased a new stake in FocalTherics in the fourth quarter worth $313,000. Finally, Flax Pond Capital LLC bought a new position in FocalTherics in the fourth quarter worth $2,623,000. Hedge funds and other institutional investors own 62.74% of the company’s stock.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.